




PHARMACEUTICAL 2023

Hoth Therapeutics Inc.
Rank 346 of 446





PHARMACEUTICAL 2023

Hoth Therapeutics Inc.
Rank 346 of 446

The relative strengths and weaknesses of Hoth Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hoth Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Hoth Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -61%, being 104% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	6,726
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,388
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	4.4
Other Expenses	6,221
Other Liabilities	250
Other Net Income	-306
Other Revenues	0
Property and Equipment	0
Research and Development	4,845
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	6,759
Liabilities	1,638
Expenses	11,066
Revenues	0
Stockholders Equity	5,122
Net Income	-11,372
Comprehensive Net Income	-11,370
Economic Capital Ratio	-61%